Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.

Abstract: The present invention relates to methods, compositions and systems for detecting perchlorate in a sample. Compositions useful for detecting perchlorate in a sample include those comprising a perchlorate reductase, a reductant and an electron shuttle. In an exemplary embodiment, the composition comprises perchlorate reductase from Dechloromonas agitata, reduced nicotinamide adenine dinucleotide and N-methylphenazinium methylsulfate. The present invention also provides for methods of using the compositions disclosed herein, as well as systems thereof. In some exemplary embodiments, the methods comprise a concentration step, in which, for example, the sample is contacted with a cationic solid phase extraction column. Employing this step provides certain advantages such as a lowered detection limit and the removal of contaminants.

Abstract: Health is a complex state that represents the continuously changing outcome of nearly all human activities and interactions. The invention provides efficient methods and arrays for health monitoring, diagnosis, treatment, and preventive care. The invention monitors a broad range of identifying molecules from a subject, such as circulating antibodies, and the invention evaluates a pattern of binding of those molecules to a peptide array. The characterization of the pattern of binding of such molecules to a peptide array with the methods of the invention provide a robust measure of a state of health of a subject.

Abstract: The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

Abstract: The invention relates to a method of immobilising at least one RNA molecule onto a surface of a support comprising: i) providing a first support having a surface on which at least one DNA molecule is immobilised, wherein the DNA molecule encodes an RNA molecule and the encoded RNA molecule comprises a binding molecule; ii) providing a second support having a surface on which at least one binding partner for interacting with the binding molecule is immobilised; iii) arranging the first and second supports such that the surfaces displaying the immobilised molecules are in close proximity and substantially face each other, and contacting the DNA molecule immobilised on the surface of the first support with transcription reagents; and iv) carrying out a transcription reaction to generate the encoded RNA molecule, wherein the RNA molecule is directly immobilised onto the surface of the second support via an interaction between the binding molecule of the RNA molecule and the binding partner on the surface of the s

Abstract: Walk-through mutagenesis and natural-variant combinatorial fibronectin Type III (FN3) polypeptide libraries are described, along with their method of construction and use. Also disclosed are a number of high binding affinity polypeptides selected by screening the libraries against a variety of selected antigens.

Abstract: The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial, fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

Abstract: The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as ?4 integrin and CD44 expression.

Abstract: An optical sensing device and associated apparatus are configured for multiplexed detection of specific analytes in fluid samples. The device has a wavelength-tunable grating-coupler configuration in which a grating is disposed on a surface of a waveguide. Different regions of the grating may be functionalized with different receptors, and may form binding-specific sensors and reference sensors. The receptors are exposed to a fluid sample utilizing a fluidic structure mounted to the device. The device utilizes evanescent waves to sense analytes bound to the waveguide surface. The evanescent wave is sensitive to changes in refractive index at (or near) the waveguide surface. Changes in refractive index occur proportionally to the mass of the bound analyte. The apparatus utilizes a tunable light source to implement swept wavelength interrogation while the input beam is held at a fixed coupling angle relative to the waveguide and grating.

Abstract: Provided is a capture nanobead with multiple oriented adapting peptides, comprising: a nanobead; and multiple adapting peptides, each adapting peptide specifically recognizing an IgG constant region or fragment thereof and being chemically conjugated with the nanobead, whereby the adapting peptides are orientedly arranged on the nanobead. The capture nanobeads is capable of binding or conjugating with capture molecules such capture antibodies, which is useful as the basis to bind to alternative antibodies or Fab fragments in sandwich immunoassays.

Abstract: The invention provides biomarkers associated with age related immune function and the use of the biomarkers to identify compositions useful for strengthening immune function in animals and to determine if an animal is responding to treatment targeted to strengthen the immune system.

Abstract: Concentrations of certain miRNA, mRNA and/or protein markers in the biological fluids and/or tissues of a subject are used to determine the probability that the subject does or does not have Posttraumatic Stress Disorder (PTSD). The concentrations of these markers in fluids and/or tissues are different in subjects with PTSD as compared to subjects who do not suffer from this disorder.

Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.

Abstract: The invention is directed to tumor associated markers (TAMs) and autoantibody biomarkers that can be used diagnostically.

Abstract: Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes.

Abstract: The invention provides single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% but not all of said variegated amino acid residue positions are located either in the loop, helix surface or linker region of the Alphabody. The invention further provides methods for use of the Alphabody libraries and Alphabodies obtainable by the methods of the invention.

Abstract: The here described invention discloses a combination of a top and bottom loop binder library using the CD and the FG loops of a number of FnIII domains (FnIII) (e.g., FnIII7, FnIII10 and FnIII14) together with the surface exposed residues of the beta-sheet. The invention also pertains to a method of forming a library of FnIII domain polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity.

Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.

Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.

Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.

Abstract: The present invention relates to a microarray comprising at least 50,000 oligopeptide features per cm2 where the oligopeptide features represent at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the proteome of a virus or an organism. The present invention further relates to methods for the synthesis of such microarrays and methods of using microarrays comprising at least 50,000 oligopeptide features per cm2. In an embodiment of the invention, the oligopeptide features represent proteins expressed in the same species, wherein the oligopeptide features are presented in a tiling pattern representing at least about 5,000 to-at least about 25,000 proteins expressed in a species. In some embodiments, the oligopeptide microarray features represent proteins expressed in the same species, wherein the microarray features are present in a tiling pattern that represents at least about 5,000 to at least about 50,000 expressed proteins.

Abstract: Provided herein is a system and method for identifying a biomarker and producing a reagent for detecting the biomarker. The system and method comprises administering to an animal a biological sample and comparing the immune response of the animal to the immune response of another animal.

Abstract: Methods are provided for determining whether a subject has a diabetes phenotype. In practicing the subject methods, a sample, e.g., a blood sample, from a subject is analyzed for the presence of one or more autoantibodies to obtain an antibody signature. The obtained antibody signature is then employed to determine whether the subject has a diabetes phenotype. The subject methods may be used in diagnostic or prognostic applications, e.g., determining whether the subject has diabetes (e.g., T1D or T2D), or monitoring a subject with diabetes to determine whether the subject has or will develop ESRD. Also provided are compositions, systems and kits that find use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the diagnosis and monitoring of diabetes in a subject.

Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.

Abstract: A process for making a micro-array. The process comprises the step of depositing a population of microbeads on a substrate having at least one fiducial. The population being comprised of at least two sub-populations, preferably multiple sub-populations, each comprising a known active agent capable of specific binding with at least one target analyte. The said subpopulations are deposited sequentially and at discrete periods of each other. The process also comprises the step of making images of the substrate after deposition of each subpopulation. The images are then compared using the fiducial as a reference to thereby determine the location of each microbead and to identify the subpopulation, and its known active agent, based on differences between each image. Also disclosed in a system for using the microarray.

Abstract: The invention provides methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers identified herein.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.

Abstract: The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.

Abstract: In accordance with one aspect of the present invention, screening and culturing devices have been developed which are useful for the identification of media which support cell viability, growth and/or proliferation, and transformation and/or differentiation. In a further aspect, screening and culturing methods employing the invention screening and culturing devices have been developed. In a still further aspect, methods for making invention screening and culturing devices have been developed.

Abstract: The invention relates to biomarkers which may be used individually or in combination to diagnose osteoarthritis. In particular, it relates to the use of one or more of V65 vitronectin fragment or fragments, variants or degradation products thereof; complement fragment C3f or fragments, variants or degradation products thereof; or a decreased concentration of CTAPIII protein or fragments, variants or degradation products thereof, as a marker of osteoarthritis.

Abstract: The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.

Abstract: The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The invention relates to the generation of immunoglobulin libraries and the identification and production of immunoglobulins having a specific functionality of interest.

Abstract: The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided.

Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.

Abstract: The invention provides methods and compositions for distinguishing ovarian cancer from a benign pelvic mass using two or more of the following biomarkers: IL-6, MMP9, tPA, IGFBP2, MMP7, Tenascin, NAP2, glycodelin, MCSF, MMP2, Inhibin A, uPAR, and EGFR. The methods are useful in distinguishing a benign pelvic mass from ovarian cancer in subjects, particularly in subjects identified as having increased CA125 levels.

Abstract: Object is to provide a method of constructing a library of peptides having, at a desired position in the random sequence of each peptide, an amino acid having a portion capable of binding to a target. The invention provides a method of producing a library of peptides having, at a designated position in the random sequence of each peptide, a special amino acid having a portion capable of binding to a target, including (i) preparing a library of mRNAs having, in the mRNA sequence coding for a random amino acid sequence, a base sequence having an altered codon encoding the special amino acid, (ii) preparing an aminoacyl tRNA with the special amino acid linked to a tRNA encoded by the altered codon, and (iii) translating the mRNAs by using a cell-free translation system containing the aminoacyl tRNA to obtain a library of peptides having, in the random sequence thereof, a predetermined special amino acid.

Abstract: The invention relates to novel marker sequences for multiple sclerosis and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for multiple sclerosis diseases using said marker sequences. The invention further relates to a diagnostic device containing such marker sequences for multiple sclerosis, especially to a protein biochip and the use thereof.

Abstract: The disclosure provides novel SLE biomarkers. The disclosure further provides kits and methods of diagnosing, prognosing, and stratifying subjects with the disease by utilizing the novel SLE biomarkers.

Abstract: The invention relates to devices and diagnostic methods using the devices for detecting the presence of neurodegenerative diseases. The device (a “biosensor”) distinguishes between different neurodegenerative diseases and facilitates pre-symptomatic diagnoses.

Abstract: This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity. The probe enables detection of proteolytic activity in extremely small volume and at low concentration. In certain embodiments the probes comprise an indicator for the detection of an active protease, where the indicator comprises a nanocrescent attached to a peptide, where said peptide comprises a recognition site for the protease and a Raman tag attached to the peptide.

Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected gene, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile.

Abstract: A naive WW domain peptide library derived from a WW domain peptide sequence which has been diversified by changing the amino acid sequence at one or more positions is provided. The naive WW domain peptide library may be derived from a GroupIV WW domain peptide. Methods for making the naive WW domain peptide library and methods for selected a modified WW domain peptide that binds a target ligand using the naive WW domain peptide library are also provided. Also disclosed are modified WW domain peptides that bind desired target ligands, pharmaceutical compositions comprising such peptides, and uses for such peptides. The modified WW domain peptides have altered, improved or different, target ligand binding characteristics to those of the unmodified WW domain peptides from which they are derived.

Abstract: The present invention is includes compositions and methods directed to the multiplexed analysis of carbohydrates and carbohydrate containing compounds. The compositions and methods utilize suspension array technology (SAT) and an array of different carbohydrate binding molecules, each carbohydrate binding molecules with a known carbohydrate binding specificity, to obtain a glycoprofile of the carbohydrate structure(s) in a sample. Each carbohydrate binding molecule of a given specificity is linked to the external surface of a population of individually addressable particles.

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract: The present invention relates to a method for obtaining cells or cell populations having a high biological activity from a biological tissue by enzymatic isolation, and probes for use in the method; more specifically to a method for analyzing a biological tissue, comprising applying two or more probes respectively containing biological-component binding domains through which two or more proteins bind to a predetermined biological component, to an isolated biological tissue, and analyzing binding amounts of the probes to the biological tissue.